TiGenix NV

General Information

(Note: Prior to this offering our ordinary shares have traded, and subsequent to this offering will continue to trade, on Euronext Brussels under the symbol “TIG.” The latest reported closing sale price of our ordinary shares on Euronext Brussels on November 25, 2016 was 0.86 euros per share, or $0.91 per share (equivalent to a price of $9.10 per ADS) based on the rate of exchange on that day.)

We are an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from our proprietary technology platforms of allogeneic, or donor-derived, stem cells. We have completed, and received positive data in, a single pivotal Phase III trial in Europe of our most advanced product candidate Cx601, a potential first-in-class injectable allogeneic stem cell therapy indicated for the treatment of complex perianal fistulas in patients suffering from Crohn’s disease. A complex perianal fistula consists of abnormal tracts between the rectum and the exterior surroundings of the anus, and is commonly associated with Crohn’s disease. It is a serious clinical condition affecting the anal sphincter and is potentially associated with a perianal abscess.

Employees: 74
Founded: 2000
Contact Information
Address Romeinse straat 12, box 2, 3001 Leuven Belgium
Phone Number +32 (16) 39 6060
Web Address https://www.tigenix.com
View Prospectus: TiGenix NV
Financial Information
Market Cap
Revenues $1.1 mil (last 12 months)
Net Income $-9.7 mil (last 12 months)
IPO Profile
Symbol TIG
Exchange NASDAQ
Shares (millions): 0.0
Price range $9.10 - $9.10
Est. $ Volume $57.5 mil
Manager / Joint Managers BofA Merrill Lynch/ Cowen and Company
CO-Managers Canaccord Genuity
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change